Precipio Announces Publication of a Joint Study with Memorial Sloan-Kettering Cancer Center Highlighting Its Cutting-Edge Bloodhound BCR::ABL1 Assay

Core Viewpoint - Precipio, Inc. has introduced the Bloodhound BCR::ABL1 assay, the first assay capable of simultaneously detecting and quantifying all four clinically relevant BCR::ABL1 isoforms for Chronic Myeloid Leukemia (CML), setting a new standard for patient monitoring [1][2]. Group 1: Assay Features and Benefits - The Bloodhound BCR::ABL1 assay allows for comprehensive monitoring of disease progression by providing multiple data points from a single test, which is crucial as 25% of patients may have multiple BCR::ABL1 breakpoints that could be missed with traditional testing methods [3]. - This assay establishes a new standard for full quantification of BCR::ABL breakpoints, enabling clinicians to monitor treatment impact and detect early relapse with precise measurements [3][4]. - The assay demonstrates high sensitivity, capable of detecting changes as low as 1 in 100,000 cells (0.001%), which is essential for monitoring measurable residual disease (MRD) [4]. Group 2: Market Position and Innovation - Precipio's Bloodhound assay is the only clinical assay that can test multiple BCR::ABL1 isoforms simultaneously, eliminating the need for separate tests and enhancing laboratory workflow [5][6]. - The assay simplifies the testing process into one standardized test that can be run in various laboratory settings, including physician office laboratories and hospitals, thus improving accessibility [2][7]. - Precipio aims to address the issue of cancer misdiagnosis through innovative diagnostic products, ultimately improving patient outcomes and reducing healthcare costs [8].